McKesson (MCK) stated Thursday it has extended its partnership with CVS Health to distribute pharmaceuticals through June 2027.
McKesson Corporation (NYSE: MCK) today announced that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies and distribution centers through June 2027. “We are pleased to continue our long-standing relationship with CVS Health and value the shared commitment of improving health
WILMINGTON, DE / ACCESSWIRE / September 27, 2022 / Transparency Market Research Inc. - Growing incidence of various chronic diseases, including cardiovascular diseases and diabetes, is generating growth opportunities in the global digital health market. This trend is further bolstered by the increasing number of geriatric individuals across the world, changing lifestyles, increasing consumption of unhealthy food products, and increase in the incidence of obesity. According to a recent research report, the global digital health market is anticipated to rise at a CAGR of 18.3% over the forecast period of 2021 to 2028. Growing adoption of next-gen digital health products by healthcare providers, such as insurance companies, and hospitals and clinics, is also influencing the development of the market. However, the high cost of installing digital health systems, such as EMR or EHR, may restrain the growth of the global digital health market in coming years. On the other hand, rising instances of collaborations amongst the players are anticipated to bode well for the development of the global digital health market in coming years.
McKesson has seen solid growth in recent years, with strong operating momentum seen in recent times, in part aided by the pandemic. Read more about MCK stock here.
Major players in the big data healthcare market are McKesson Corporation, Cognizant Technology Solutions Corporation, Epic Systems Corporation, Cerner Corporation, Dell Inc, GE Healthcare, Optum Inc, Siemens AG, Koninklijke Philips NV, Xerox Holdings Corporation, Allcripts Healthcare Solutions Inc, International Business Machines Corporation, Oracle Corporation, Microsoft Corporation and Hewlett-Packard Company. Major players in the big data healthcare market are McKesson Corporation, Cognizant Technology Solutions Corporation, Epic Systems Corporation, Cerner Corporation, Dell Inc, GE Healthcare, Optum Inc, Siemens AG, Koninklijke Philips NV, Xerox Holdings Corporation, Allcripts Healthcare Solutions Inc, International Business Machines Corporation, Oracle Corporation, Microsoft Corporation and Hewlett-Packard Company.
CHARLESTON, W.Va. (AP) — Walmart and CVS Pharmacy have settled with the state of West Virginia for a combined total of $147 million in a lawsuit over the companies’ roles in contributing to the oversupply of prescription drugs that fueled the opioid epidemic in the country’s most impacted state, Attorney General Patrick Morrisey announced Tuesday. Walmart and CVS were two lawsuits that were part of a larger trial that was pushed back to June of next year along with Kroger and Walgreens. Morrisey recently announced a settlement with Rite Aid for up to $30 million to resolve similar litigation. The lawsuits allege the pharmacies’ contributions to the oversupply of prescription opioids in the state have caused “significant losses through their past and ongoing medical treatment costs, including for minors born addicted to opioids, rehabilitation costs, naloxone costs, medical examiner expenses, self-funded state insurance costs and other forms of losses to address opioid-related afflictions and loss of lives.” It brings the total settlements by the state in opioid lawsuits to $875 million, including $296 million with manufacturers, $400 million with wholesalers and $177.5 million involving pharmacies. “These settlements won’t bring back the lives lost from the opioid epidemic, but these and other settlements will hopefully provide significant help to those affected the most by this crisis in our state,” Morrisey said during a news conference. “This development also avoided a costly and lengthy trial and at the end of the day, West Virginia will have the highest per capita settlement results in the nation fighting for our people.” Walmart agreed to a settlement of just over $65 million and CVS for $82.5 million.
Healthcare services provider McKesson (NYSE:MCK) has agreed to acquire prescription price transparency and benefit analytics provider Rx Savings Solutions in a deal valued at $875 million. This includes an upfront payment of $600 million and a maximum contingent payment of $275 million. The move boosts MCK’s position in access and affordability while also laying the groundwork for an expansion of adherence, outcome management as well as biopharma (evidence-based), and payer services for the company.
Drug distributor McKesson Corporation said on Monday it would acquire private pharma technology firm Rx Savings Solutions for up to $875 million. The company helps health insurers and employers seek lower cost prescription medicines, and also provides ongoing medication reminders to help improve adherence to prescriptions. “Rx Savings Solutions’ offerings for employers and patients will […]
In this article, we discuss the top 5 stock picks of Henrik Rhenman’s Rhenman Partners. If you want our detailed analysis of Rhenman Partners’ history, investment philosophy, and hedge fund performance, go directly to Top 10 Stock Picks of Henrik Rhenman’s Rhenman Partners. 5. McKesson Corporation (NYSE:MCK) Rhenman Partners’ Stake Value: $29,082,000 Percentage of Rhenman […]
McKesson Corporation with ticker code (MCK) have now 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 409 and 320 calculating the average target price we see 380.46. With the stocks previous close at 360.8 this would indicate that there is a potential upside of 5.4%. The day 50 moving average is 344.61 and the 200 day MA is 297.73. The company has a market capitalisation of $52,743m. Find out more information at: https://www.mckesson.com [stock_market_widget type="chart" template="basic" color="green" assets="MCK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $55,617m based on the market concensus. McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S.
Healthcare Information Software market New Jersey, NJ -- ( SBWIRE ) -- 09/07/2022 -- The Latest Released Healthcare Information Software market study has evaluated the future growth potential of Global Healthcare Information Software market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Healthcare Information Software market. The study includes market share analysis and profiles of players such as GE Healthcare, Siemens Healthcare, 3M Health, McKesson, Philips Healthcare, Allscripts, Dell, Epic Systems, NextGen Healthcare, Merge Healthcare, Neusoft, InterSystems, Cerner, Carestream Health & Meditech. If you are a Healthcare Information Software manufacturer and would like to check or understand policy and regulatory proposal, designing clear explanations of the stakes, potential winners and losers, and options for improvement then this article will help you understand the pattern with Impacting Trends.
Major players in the healthcare electronic data interchange market are McKesson Corporation, Optum Inc, Allscripts Healthcare Solutions Inc. , Athenahealth Inc, NextGen Healthcare Inc, Experian plc, Cognizant Technology Solutions, Cerner Corporation, Synnex Corporation, The SSI Group LLC, Waystar Health, Comarch SA, Axway Software, PLEXIS Healthcare Systems Inc, Archer Software, TrueCommerce B2BGateway, DiCentral Corporation, 123 EDI, and Quadax Inc. Major players in the healthcare electronic data interchange market are McKesson Corporation, Optum Inc, Allscripts Healthcare Solutions Inc. , Athenahealth Inc, NextGen Healthcare Inc, Experian plc, Cognizant Technology Solutions, Cerner Corporation, Synnex Corporation, The SSI Group LLC, Waystar Health, Comarch SA, Axway Software, PLEXIS Healthcare Systems Inc, Archer Software, TrueCommerce B2BGateway, DiCentral Corporation, 123 EDI, and Quadax Inc.
The Wireless Medical Technologies market research report delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. The Wireless Medical Technologies report also incorporates the current and future global market outlook in the emerging and
As of Thursday, McKesson Corporation’s (NYSE:MCK) stock closed at $363.83, down from $367.00 the previous day. While McKesson Corporation has underperformed by -0.86%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MCK rose by 79.24%, with highs and lows ranging from $375.23 to $193.89, whereas the […]
CONCORD, N.H. (AP) — Drugmaker Johnson & Johnson has agreed to pay $40.5 million in a settlement with New Hampshire over its role in the opioid addiction crisis, days before the case was scheduled for trial, the state attorney general’s office said Thursday. The state filed a lawsuit against Johnson & Johnson and a subsidiary in 2018, alleging that they aggressively marketed their opioids to prescribers and patients in New Hampshire and misrepresented that their opioids were safer than other alternatives. The lawsuit also alleged that Johnson & Johnson made misleading statements about opioids; misrepresented that its opioids were rarely addictive when used for chronic pain; and targeted vulnerable populations, such as the elderly. “This resolution provides a positive step forward in ensuring these devastating business practices are not repeated, and that resources are allocated to help stem the tide of the opioid crisis,” Gov. Chris Sununu said in a statement. Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., denied the state’s claims, saying it truthfully marketed its prescription opioids, which accounted for a small share of the opioid medications prescribed in New Hampshire, complied with all applicable laws and regulations, did not cause the harm alleged by the state. “This settlement is not an admission of liability or wrongdoing and marks continued progress in resolving opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States,” Johnson & Johnson said in a statement. “The Company will continue to defend against any litigation that the final agreement does not resolve.” New Hampshire was one of a few states that did not join a national settlement with the company in February because its opioid crisis was “particularly severe” and because the state had already devoted “significant litigation resources” in preparation for trial, the attorney general office’s news release said.
McKesson Corporation with ticker code (MCK) have now 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 409 and 320 with the average target price sitting at 380.46. Now with the previous closing price of 364.02 this is indicating there is a potential upside of 4.5%. The 50 day moving average now sits at 335.99 while the 200 day moving average is 292.06. The market cap for the company is $52,206m. Company Website: https://www.mckesson.com [stock_market_widget type="chart" template="basic" color="green" assets="MCK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $54,563m based on the market concensus. McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.
In this article, we discuss the 5 stocks that Warren Buffett loaded up on for the rest of 2022. If you want to see more stocks in this selection, click Warren Buffett Loaded Up on These 10 Stocks for the Rest of 2022. 5. McKesson Corporation (NYSE:MCK) Number of Hedge Fund Holders: 59 McKesson Corporation […]
Related Stocks: EMBC , MCK , CAH , REGN , ENTA ,
Check out Andreas Halvorsen Stock Picks » Download GuruFolio Report of Andreas Halvorsen (Updated on 08/14/2022) Related Stocks: ELV , CMCSA , MCK , AIG , TMUS ,
Berkshire Hathaway (BRK.B) (BRK.A) increased its stakes in Ally Financial (ALLY), Occidental Petroleum (OXY), Activision Blizzard (ATVI), Markel (MKL), and McKesson (MCK) and exited…
Wholesale drug distributors Cardinal Health (CAH) and McKesson both hit 52-week highs today of, respectively, $71.45 and $371.92.
BeiGene (BGNE) signed a strategic agreement with McKesson''s (MCK) unit Ontada to improve U.S
McKesson Corporation with ticker code (MCK) now have 13 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 409 and 320 calculating the average target price we see 377.92. Now with the previous closing price of 354.77 this would imply there is a potential upside of 6.5%. The day 50 moving average is 326.01 and the 200 moving average now moves to 284.34. The company has a market cap of $51,687m. Company Website: https://www.mckesson.com [stock_market_widget type="chart" template="basic" color="green" assets="MCK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $55,059m based on the market concensus. McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S.
Big Data Analytics in Healthcare Market 2022-2028 New Jersey, NJ -- ( SBWIRE ) -- 08/10/2022 -- The Latest research study released by HTF MI "Global Big Data Analytics in Healthcare Market" with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Some of the Major Companies covered in this Research are Allscripts, Cerner Corporation, Cisco, Citius Tech, Cognizant, Cotiviti, Dell, Epic System Corporation, GE Healthcare, Health Catalyst, IBM, Innovalon, McKesson, MEDEANALYTICS, Microsoft, Optum, Oracle, Philips, SAS Institute, SCIO Health Analytics, Siemens, Viteros Health, Wipro & Xerox Corporation etc. Click here for free sample + related graphs of the report @: https://www.htfmarketreport.com/sample-report/3847184-2022-2030-report-on-global-big-data-analytics-in-healthcare-market Browse market information, tables and figures extent in-depth TOC on "Big Data Analytics in Healthcare Market by Application (Financial Analytics, Operational Analytics, Population Health Analytics, Clinical Data Analytics & Other), by Product Type (, Services, Software & Hardware), Business scope, Manufacturing and Outlook – Estimate to 2027". for more information or any query mail at sales@htfmarketreport.com At last, all parts of the Global Big Data Analytics in Healthcare Market are quantitatively also subjectively valued to think about the Global just as regional market equally.
McKesson (MCK) hit a 52-week high on Tuesday of $358.64. The wholesale drug distributor is up 44% year-to-date.
NEW YORK , Aug. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MU, STZ, NVAX, MCK, and CI. … Full story available on Benzinga.com
https://www.investing.com/news/pro/mckesson-pt-raised-to-409-at-deutsche-bank-432SI-2866678
McKesson performed well during times of low consumer confidence in the last 20 years. See why we expect MCK stock to outperform broader market in the near term.
https://www.investing.com/news/pro/mckesson-pt-raised-to-400-at-ubs-432SI-2863548
McKesson Corp (NYSE: MCK ) reported Q1 FY23 adjusted EPS of $5.83 , +5% Y/Y, beating the consensus of $5.27. Revenues increased 7% Y/Y to $67.15 billion, surpassing the consensus of $65.14 billion. U.S. Pharmaceutical segment''s revenues were $56.9 billion, +14%, driven by an increased volume of specialty products, including higher volumes from retail national account customers, and market growth, partially offset by branded to generic … Full story available on Benzinga.com
McKesson Corporation with ticker code (MCK) now have 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 400 and 320 and has a mean target at 371.62. Given that the stocks previous close was at 335.09 this is indicating there is a potential upside of 10.9%. There is a 50 day moving average of 324.31 and the 200 day moving average is 280.74. The market cap for the company is $46,965m. Visit the company website at: https://www.mckesson.com [stock_market_widget type="chart" template="basic" color="green" assets="MCK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $52,085m based on the market concensus. McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S.
Tennessee’s attorney general said Wednesday he has sued Walgreens, accusing the drugstore chain of contributing to the state’s opioid crisis by failing to maintain effective controls against the abuse of prescription pain pills. The lawsuit seeking unspecified civil penalties was filed in Knox County Circuit Court by Attorney General Herbert H. Slatery III and alleges violations of Tennessee’s Consumer Protection Act. The lawsuit said that between 2006 and 2020, Walgreens retail stores in Tennessee dispensed more than 1.1 billion oxycodone and hydrocodone pills. One pharmacy alone in Jamestown dispensed enough opioids over that period to supply each resident with 2,104 pills. “Walgreens did not flood the State of Tennessee with opioids by accident,” Slatery said in a statement. “Rather, the fuel that Walgreens added to the fire of the opioid epidemic was the result of knowing — or willfully ignorant — corporate decisions. Walgreens ignored numerous red flags and failed to detect and prevent the abuse and diversion of dangerous narcotics.” Walgreens did not offer immediate comment Wednesday.
McKesson boosted its fiscal 2023 adjusted diluted EPS outlook following strong FQ1 2023 operating performance.
(RTTNews) - McKesson Corporation (MCK) Wednesday reported first-quarter net income of $768 million or $5.26 per share, compared to $486 million or $3.07 per share last year. Adjusted earnings per share for the quarter was $5.83, up from $5.56 last year. Revenues for the first quarter rose 7% to $67.2 million from $62.7 million last year.
IRVING, Texas (AP) _ McKesson Corp. (MCK) on Wednesday reported fiscal first-quarter earnings of $768 million. On a per-share basis, the Irving, Texas-based company said it had profit of $5.32. Earnings, adjusted for one-time gains and costs, were $5.83 per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of $5.31 per share. The prescription drug distributor posted revenue of $67.15 billion in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $63.87 billion. McKesson expects full-year earnings in the range of $23.95 to $24.65 per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MCK at https://www.zacks.com/ap/MCK
McKesson (MCK) is scheduled to announce Q1 earnings results on Wednesday, August 3rd, after market close.The consensus EPS Estimate is $5.30 (-4.7% Y/Y) and the consensus Revenue…
McKesson (NYSE: MCK ) has outperformed the market over the past 5 years by 6.33% on an annualized basis producing an average annual return of 17.01%. Currently, McKesson has a market capitalization of $49.16 billion. Buying $100 In MCK: If an … Full story available on Benzinga.com
CHARLESTON, W.Va. (AP) — West Virginia cities and counties reached a $400 million tentative settlement with three major U.S. drug distributors, lawyers announced Monday. In a lawsuit in state court, the cities and counties accused the distributors of fueling the opioid epidemic. The companies are AmerisourceBergen, Cardinal Health and McKesson. The funds will be distributed over 12 years. “This is a monumental settlement for the state of West Virginia, and it’s been a battle that’s been waged by a lot of families, a lot of communities,” Wheeling attorney Bob Fitzsimmons told news outlets. “A lot of bad things have happened as a result of the opioid epidemic.” Fitzsimmons and Huntington attorney Paul Farrell Jr. said the individual counties and municipalities still must approve the settlement. Lauren Esposito, vice president of external and executive communications for AmerisourceBergen, said the settlement will avoid years of litigation and help get resources to areas affected by opioid misuse, as well as make sure health care facilities are able to access medications that patients and providers need, news outlets reported.
Three leading drug distributors in the U.S., McKesson (MCK), AmerisourceBergen (ABC), and Cardinal Health (CAH), have struck a $400M settlement with West Virginia''s cities and counties…
West Virginia’s cities and counties reached a $400 million settlement on Monday with drug distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, resolving the local governments’ allegations that the three companies fueled an opioid crisis in the state. More than 100 local governments had sued the drug distributors, alleging they recklessly oversupplied West Virginia […]
Key Events This Busy Week: Jobs, ISM, And Even More Central Banks And Earnings After a frenzied week which saw not just the US slide into technical recession just hours after the Fed hiked rates by a whopping 75bps for the 2nd time in a row (hence accelerating the US slowdown), as well as record bonanza of corporate earnings, markets still won''t get the chance with US payrolls on Friday, followed by CPI on Wednesday 10th. If nothing out of the ordinary occurs in these two prints though maybe we can have a quiet two or three weeks according to DB''s Jim Reid, who however notes that if payrolls are far from consensus and/or CPI is strong then "we may have some fun and games in August. It’s a month of low liquidity and if something big happens it can be multiplied in such thin trading." Outside of payrolls, the other most important events this week include the manufacturing PMIs and ISM today, the RBA decision and US JOLTS tomorrow, services PMIs and ISM Wednesday, and the likely biggest hike from the BoE for 27 years alongside the increasingly important US jobless claims data on Thursday.
Related Stocks: SGEN , VRTX , MCK , MDT , ISRG ,
HARRISBURG, Pa. (AP) — A former opioid manufacturer has agreed in principle to pay up to $2.4 billion in a deal with a dozen states over its marketing and product safety practices, state attorneys general announced Friday. The company, Allergan, is now part of AbbVie but sold its generics division Actavis, including its opioid products, to Teva Pharmaceuticals six years ago. Under the settlement, payments will be made to state and local governments, Pennsylvania Attorney General Josh Shapiro said. The agreement means pharma companies have consented to pay more than $40 billion to settle opioid crisis claims regarding manufacturers and distributors, The Associated Press has found. The agreement came days after a similar, $4.3 billion agreement was reached with Teva Pharmaceuticals. A message seeking comment were left Friday with a corporate spokesperson for Teva. Shapiro said the settlement involved claims that Allergan, which produced Norco and Kadian brand generic opioids, downplayed the risk of addiction in marketing and did not act sufficiently to prevent the drugs from being improperly diverted. “No amount of money will bring back the lives we lost, but today’s agreement will help ensure we can fund the programs Pennsylvania counties need for our communities to recover from this crisis,” Shapiro said in a statement.
McKesson Corporation with ticker code (MCK) have now 13 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 395 and 320 calculating the mean target price we have 369.92. With the stocks previous close at 337.67 this now indicates there is a potential upside of 9.6%. The 50 day moving average now sits at 323.06 and the 200 day MA is 277.35. The market capitalisation for the company is $49,039m. You can visit the company''s website by visiting: https://www.mckesson.com [stock_market_widget type="chart" template="basic" color="green" assets="MCK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $53,723m based on the market concensus. McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
McKesson stock briefly broke out Monday after the drug distributor raised its dividend and announced a new deal for a cancer-related drug.
McKesson (MCK) declares $0.54/share quarterly dividend, 14.9% increase from prior dividend of $0.47.
Investors seeking shelter from the market selloff are looking for some of the best cash cow stocks. Such a move is not surprising given that robust cash flow becomes more even valuable during economic downturns. For instance, the Pacer US Cash Cows 100 ETF (BATS: COWZ ) is currently down 6.6% year-to-date (YTD) compared with the 17% loss for the S&P 500 index. The fund has seen assets under management skyrocket from $1.3 billion at the start of 2022 to the current $5.9 billion. Amid the market volatility and interest rate hikes, investors are increasingly focused on businesses with strong cash flows and healthy balance sheets. These firms typically boast positive earnings and generate more cash than they need to run the business. Moreover, they often have flexibility for continued dividend payments and stock repurchases despite macroeconomic headwinds. In addition, the market selloff provides these cash cow stocks with buying opportunities to invest in new growth opportunities at attractive valuations. 7 Best Reddit Stocks to Buy Now With that information, here are seven of the best cash cow stocks that could gain traction in the rest of the year: Ticker Company Price AZO AutoZone, Inc. $2,140.74 BMY Bristol-Myers Squibb Company $73.04 CSCO Cisco Systems, Inc. $44.54 KLAC KLA Corporation $355.04 KR The Kroger Co. $46.22 MCK McKesson Corporation $331.33 MRNA Modern, Inc. $164.92 Best Cash Cow Stocks: Autozone (AZO) Source: Robert Gregory Griffeth / Shutterstock.com 52-week range: $1,503.30 – $2,267.40 Our first cash cow stock is Autozone (NYSE: AZO ), a leading retailer and distributor of automotive replacement parts and accessories.
Published on July 23rd, 2022 by Felix Martinez Berkshire Hathaway (BRK.B) has an equity investment portfolio worth more than $360 billion as of the end of the 2022 first quarter. Berkshire Hathaway’s portfolio is filled with quality stocks. You can ‘cheat’ from Warren Buffett stocks to find picks for your portfolio. That’s because Buffett (and […] The post Warren Buffett Stocks: McKesson Corporation appeared first on Sure Dividend .
McKesson Corporation (NYSE:MCK) concluded the trading at $330.44 on Friday, July 22 with a rise of 0.80% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $327.81 and 5Y monthly beta was reading 0.72 with its price kept floating in the range … McKesson Corporation (MCK) At $330.44: Is It Worth Your Interest? Read More »
McKesson Corporation found using ticker (MCK) now have 13 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 395 and 320 calculating the mean target price we have 369.92. With the stocks previous close at 329.97 this would imply there is a potential upside of 12.1%. The day 50 moving average is 322.32 and the 200 day moving average is 273.97. The company has a market capitalisation of $47,159m. Visit the company website at: https://www.mckesson.com [stock_market_widget type="chart" template="basic" color="green" assets="MCK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $52,869m based on the market concensus. McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products.